E.g., 06/13/2021
E.g., 06/13/2021
Title Category Credit Event Date Price
Common Dilemmas in Prostate Cancer Detection and Management Webcast (2020)
    • 1.50 AMA PRA Category 1 Credit™
    • 1.50 Non-Physician Participation
$0.00 Course participants will:Optimally use PSA and other biomarkers to minimize unnecessary testing and biopsy when screening men who are at average risk for prostate cancer.Understand the principles of “risk-adapted” screening for men at elevated risk for prostate cancer based on race, family history, early in life PSA, polygenic risk scores, and specific genetic mutations (eg BRCA1/2).Understand the roles of MRI, high frequency ultrasound and novel transperineal approaches to improve prostate biopsy.
CPS Castration-Resistant Prostate Cancer Amendment (2018)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Member only benefit! AUA Guidelines provide a comprehensive and rigorous summary of evidence relating to a variety of disease conditions, providing an indispensable resource for urologic education. The Clinical Problem Solving (CPS) Protocols guideline-based Case Scenarios were designed to help maximize the impact of the guidelines. The goal of this Guideline is  to provide a rational basis for treatment of patients with CRPC, based on currently available published data.
Diagnosis and Management of Localized, Locally Advanced and Advanced Kidney Cancer Webcast (2020)
    • 1.50 AMA PRA Category 1 Credit™
    • 1.50 Non-Physician Participation
$0.00 Kidney cancer is not a single disease, it is made up of a number of different types of cancer, each with a different histology, a different clinical course, responding differently to therapy and caused by different genes. After completing this course, attendees be able to describe the different types of kidney cancer and the genes that cause each. They will learn how to identify the different types of inherited versus sporadic forms of kidney cancer.
Diagnosis and Management of Localized, Locally Advanced and Advanced Kidney Cancer Webcast (2021)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Kidney cancer is not a single disease, it is made up of a number of different types of cancer, each with a different histology, a different clinical course, responding differently to therapy and caused by different genes. After completing this course, attendees be able to describe the different types of kidney cancer and the genes that cause each. They will learn how to identify the different types of inherited versus sporadic forms of kidney cancer.
Engaging Disparities in Prostate Cancer Care (2021)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
06/28/2021 $0.00
Genetic Testing and Personalized Medicine in Prostate Cancer Podcast (2020)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Genetic Testing in Prostate Cancer: Considerations for Urologists and Their Patients Webcast (2020)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00
Immune Checkpoint Inhibitors in RCC Podcast (2020)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Incorporating Genomic Testing For Prostate Cancer into Your Practice Webcast (2021)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 There are multiple genomic tests currently available for men with localized prostate cancer. The outcomes of these tests may lead to different treatment decisions (active surveillance, surgery, radiation, etc) or impact the frequency of monitoring. The availability and marketing of genomic testing has outpaced a reflective, evidence based medicine approach to using these tests.
Integrating Care for Oncology Patients: Establishing a Multidisciplinary Oncology Clinic with Advanced Therapeutics Webcast (2020)
    • 1.50 AMA PRA Category 1 Credit™
    • 1.50 Non-Physician Participation
$0.00 This course will provide the framework to create a multidisciplinary clinic for the treatment of urologic malignancies, with representation of urologists, medical oncologists and additional specialists working together in a team-based approach. The course will focus on integration of advanced therapeutics including immune-based therapy where applicable in a multidisciplinary setting.
Life Long Learning Prep Course Webcast: Module 1: Oncology, Urinary Diversion and Adrenal + Core (2020) $1,055.00 Specifically designed for anyone unable to get away from the office to attend the Live Course, the Webcast option delivers the same great content. Purchase of the Webcast features simultaneous presentation slides and audio recorded from the Live Course and includes access to online course materials.
Management of NMIBC: Practical Solutions for Common Problems Webcast (2020)
    • 1.50 AMA PRA Category 1 Credit™
    • 1.50 Non-Physician Participation
$0.00 This course will review the most recent AUA practice guidelines for non-muscle-invasive bladder cancer and detail strategies to manage common clinical predicaments involved in the management of these tumors. Specifically we will review: the AUA guidelines; risk stratification and use of cystectomy; selection of the optimal intravesical agent at the right schedule; and treatment of toxicity from intravesical therapy. Practical solutions will be presented that can be readily integrated into the office setting.
Metastatic Hormone Sensitive Prostate Cancer: Expert Guidance for Urologists Webcast (2021)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 In just the last decade, the FDA has approved several new therapies for the treatment of prostate cancer. It is critical for urologists to understand the sequencing of agents for the treatment of mHSPC because of the overlapping toxicities and the increasing role for treating mHSPC patients. For each new agent, urologists should be able to identify the active agents and their mechanism of action, analyze the breakthrough treatments in the management of advanced and mHSPC, and describe the indications and combinations for treatment with approved agents in the management of mHSPC.
PARP Inhibitors: Assessing the Clinical Trial Landscape Webcast (2021)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 PARP Inhibitors: From Research to Practice, an exciting new educational initiative, is a series of three interactive, case-based, live virtual courses, featuring a unique topic related to PARP Inhibitors. For each session, a Moderator will engage two other subject matter experts in an interactive, interview-style presentation and discussion. 
PARP Inhibitors: Assessing the Rapidly Evolving Treatment Landscape Webcast (2021)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 PARP Inhibitors: From Research to Practice, an exciting new educational initiative, is a series of three interactive, case-based courses, featuring a unique topic related to PARP Inhibitors. For each session, a Moderator will engage two other subject matter experts in an interactive, interview-style presentation and discussion. 

Pages